Company Encyclopedia
View More
name
Zevra Therapeutics
ZVRA.US
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 1/2 clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome.
4.513 T
ZVRA.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking28/183
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE29.58%A
    • Profit Margin41.86%A
    • Gross Margin95.25%A
  • Growth ScoreA
    • Revenue YoY244.60%A
    • Net Profit YoY133.48%A
    • Total Assets YoY41.02%A
    • Net Assets YoY90.86%A
  • Cash ScoreB
    • Cash Flow Margin281.14%C
    • OCF YoY244.60%A
  • Operating ScoreC
    • Turnover0.37C
  • Debt ScoreC
    • Gearing Ratio50.70%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Zevra Therapeutics (ZVRA): Evaluating Valuation Following High-Profile Board Appointment and CFO Transition

    Zevra Therapeutics (ZVRA) has appointed Alicia Secor to its Board of Directors and announced the departure of CFO R. LaDuane Clifton. The company's shares have dropped 18% in the past month, with a 1-year total shareholder return of -11%, but a 3-year return of 85%. Analysts suggest the stock is undervalued with a fair value of $23.22, nearly triple its last close price of $8.34. Key challenges include slow adoption of therapies and reliance on a narrow pipeline.

    Simplywall·
    US
    ZVRA
    -0.12%
    Simplywall·
    US
    ZVRA
    -0.12%

    Zevra Therapeutics Announces Board Changes

    Zevra Therapeutics announced the resignation of Wendy Dixon from its Board, effective December 2, 2025, with Alicia Secor appointed as her successor. There was no disagreement with the company regarding Dixon's resignation. The changes were disclosed in an SEC filing dated December 2, 2025.

    TradingView·
    US
    ZVRA
    -0.12%
    TradingView·
    US
    ZVRA
    -0.12%

    The Nasdaq Biotechnology Index rose over 2.1%

    The Nasdaq Biotechnology Index rose by more than 2.1%. Among the constituent stocks, Personalis rose by 16.18%, Pacific Biosciences of California rose by 14.89%, Adaptive Biotechnologies rose by 12.37%, Twist Bioscience rose by 11.66%, 10X Genomics rose by 10.02%, Cullinan Oncology LLC rose by 10.21%, and Alumis rose by 9.97%. Meanwhile, Tscan Therapeutics fell by 3.56%, Applied Therapeutics fell by 7.34%, and Zevra Therapeutics fell by 7.40%

    Wallstreetcn·
    US
    ADPT
    -11.77%
    US
    ZVRA
    -0.12%
    US
    TXG
    -3.03%
    Wallstreetcn·
    US
    ADPT
    -11.77%
    US
    ZVRA
    -0.12%
    US
    TXG
    -3.03%

    Zevra Therapeutics Announces CFO Resignation

    Zevra Therapeutics announced the resignation of CFO R. LaDuane Clifton, effective December 31, 2025, as he pursues other professional opportunities. Replacement details are not disclosed.

    TradingView·
    US
    ZVRA
    -0.12%
    TradingView·
    US
    ZVRA
    -0.12%

    Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Consensus Rating of "Moderate Buy" from Analysts

    Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has received a consensus "Moderate Buy" rating from eight brokerages. The stock has a 1-year price target of $22.80. Recent analyst actions include price target adjustments by Canaccord Genuity and JMP Securities. The stock opened at $8.88, with a 1-year range of $6.19 to $13.16. Recent insider transactions include a purchase by Director John B. Bode and a sale by CEO Neil F. Mcfarlane. Institutional investors have shown increased interest in the stock.

    Market Beat·
    US
    ZVRA
    -0.12%
    Market Beat·
    US
    ZVRA
    -0.12%
    © 2025 Longbridge｜Disclaimer